Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Baxter International has announced plans to construct a new manufacturing site in Georgia to support growth of its plasma-based treatments, which include treatments for immune disorders, trauma and other critical conditions.
Subscribe to our email newsletter
The new site will facilitate operations supporting plasma fractionation, purification, fill-finish and a testing lab.
Commercial production is scheduled to begin in 2018, with the new plasma fractionation facility adding up to three million liters of new capacity annually when fully operational, the company said.
Baxter chairman and chief executive officer Robert Parkinson said, ”This investment demonstrates our long-term commitment to patients around the world who rely on our plasma-based therapies.”
The company anticipates that the capital investments at the new Covington site will exceed $1bn over the next five years.
With the investment, the company expects creation of more than 1,500 full-time positions in Georgia and more than 2,000 jobs in total across multiple US locations.